EGFR

Overview

EGFR, the epidermal growth factor receptor, is a transmembrane receptor tyrosine kinase encoded by the EGFR gene. It belongs to the ERBB family of receptors and is activated by ligands such as epidermal growth factor. Upon activation, EGFR triggers intracellular signaling cascades including the PI3K/AKT/mTOR, JAK2/STAT3, and MAPK pathways, which regulate cell proliferation, survival, migration, differentiation, and tissue repair. Because of this central signaling role, EGFR is a major biological regulator in normal physiology and a prominent therapeutic target in oncology.

Clinically, EGFR is best known for its role in EGFR-mutated non-small cell lung cancer (NSCLC), where activating mutations can drive tumor growth and confer sensitivity to EGFR-targeted tyrosine kinase inhibitors (TKIs). EGFR signaling is also implicated in resistance biology, including bypass signaling through MET, interactions with HER2, and receptor stabilization mechanisms involving ubiquitin-dependent degradation. Beyond cancer, EGFR-associated signaling has also been studied in tissue regeneration and wound repair.

Focus of Latest Publications

Recent studies centered on EGFR largely reflect its continued importance as a therapeutic target in EGFR-mutated NSCLC and as a signaling node in resistance and combination-treatment strategies.

Several publications examined EGFR-TKIs across different generations in advanced EGFR-mutated NSCLC. A real-world study compared first- and third-generation EGFR-TKIs for advanced disease, reflecting ongoing evaluation of treatment sequencing and effectiveness in routine practice. Another observational study reported on afatinib 30 mg daily in patients with advanced NSCLC harboring common EGFR mutations, reinforcing afatinib’s role as an approved first-line option for sensitizing EGFR mutations. A phase III trial, AENEAS2, evaluated aumolertinib with or without chemotherapy in advanced EGFR-mutated NSCLC, noting that third-generation EGFR-TKIs are standard first-line therapies but that resistance and progression remain major limitations.

Resistance biology was a major theme. One real-world study of vebreltinib plus EGFR-TKI in EGFR-mutated NSCLC with MET-driven resistance highlighted MET amplification/overexpression as a key bypass mechanism of resistance to EGFR-TKIs. Another study on acquired TKI resistance in murine RET+ lung adenocarcinoma found that resistant tumors and derived cell lines showed sensitivity to MET- and ERBB-targeted TKIs, indicating bypass signaling through receptor tyrosine kinases. These findings align with broader evidence that EGFR-targeted therapy often requires combination strategies when tumors activate alternative signaling routes such as EGFR-MET or other ERBB-family pathways.

EGFR also appeared in studies of metastatic disease management. A multicenter propensity-matched analysis assessed the clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC, including approaches such as (chemo)radiotherapy and consolidative surgery. In a separate case-based report, osimertinib re-escalation with filgrastim support was used to rescue a suprasellar metastasis in EGFR-mutant NSCLC, underscoring the challenge of maintaining adequate EGFR-TKI exposure in lung cancer brain metastases and other CNS sites when toxicity limits dosing.

Beyond lung cancer, EGFR was implicated in additional mechanistic and translational studies. In hepatocellular carcinoma, ACSS2-driven palmitate biosynthesis was reported to facilitate EGFR palmitoylation, protecting the receptor from ubiquitin-dependent degradation and contributing to lenvatinib resistance. In esophageal squamous cell carcinoma cells, epigallocatechin gallate (EGCG) attenuated arecoline-induced migration and invasion through EGFR/AKT/P38 signaling, suggesting a role for EGFR-linked pathways in metastasis-related phenotypes. In HER2-related resistance biology, one study reported that EGFR inhibition restored trastuzumab sensitivity, supporting cross-talk between EGFR and HER2-directed therapy responses.

EGFR signaling was also connected to tissue regeneration and biomaterial-based repair. A dual-enzyme cascade protein hydrogel membrane study found that a biomaterials-based system activated EGFR-associated signaling pathways (PI3K/AKT/mTOR) and improved diabetic wound repair, indicating that EGFR can be leveraged outside oncology to promote regeneration and restore dermal architecture. Collectively, these studies reinforce EGFR as a central signaling hub in cancer progression, drug resistance, and tissue repair.